Your search returned 47 results.

Results
	1.	Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man. [electronic resource] by Foley, James E Publication details: Frontiers in endocrinology 2019 In: Frontiers in endocrinology vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Estimation of the Relative Contribution of Postprandial Glucose Exposure to Average Total Glucose Exposure in Subjects with Type 2 Diabetes. [electronic resource] by Ahrén, Bo Foley, James E Producer: 20160916 In: International journal of endocrinology vol. 2016 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism. [electronic resource] by Ahrén, Bo Foley, James E Producer: 20170123 In: Diabetologia vol. 59 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. [electronic resource] by Foley, James E Jordan, Jens Producer: 20101203 In: Vascular health and risk management vol. 6 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. [electronic resource] by Foley, James E Ahrén, Bo Publication details: European endocrinology Aug 2017 In: European endocrinology vol. 13 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. [electronic resource] by Schweizer, Anja Dejager, Sylvie Foley, James E Producer: 20121002 In: Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 3 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus. [electronic resource] by Dejager, Sylvie Schweizer, Anja Foley, James E Producer: 20120904 In: Vascular health and risk management vol. 8 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	DPP-4 inhibitor treatment: β-cell response but not HbA [electronic resource] by Kozlovski, Plamen Bhosekar, Vaishali Foley, James E Producer: 20170731 In: Vascular health and risk management vol. 13 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Blood pressure and fasting lipid changes after 24 weeks' treatment with vildagliptin: a pooled analysis in >2,000 previously drug-naïve patients with type 2 diabetes mellitus. [electronic resource] by Evans, Marc Schweizer, Anja Foley, James E Producer: 20170221 In: Vascular health and risk management vol. 12 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	10.	Effect of vildagliptin as add-on therapy to a low-dose metformin. [electronic resource] by Filozof, Claudia Schwartz, Sherwyn Foley, James E Producer: 20110714 In: World journal of diabetes vol. 1 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	11.	Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients? [electronic resource] by Foley, James E Bhosekar, Vaishali Kawamori, Ryuzo Producer: 20161101 In: Vascular health and risk management vol. 12 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	12.	Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease? [electronic resource] by Evans, Marc Dejager, Sylvie Schweizer, Anja Foley, James E Producer: 20150326 In: Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 6 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	13.	Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin. [electronic resource] by Schweizer, Anja Foley, James E Kothny, Wolfgang Ahrén, Bo Producer: 20130812 In: Vascular health and risk management vol. 9 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	14.	Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies. [electronic resource] by Schweizer, Anja Dejager, Sylvie Foley, James E Kothny, Wolfgang Producer: 20110613 In: Vascular health and risk management vol. 7 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	15.	Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. [electronic resource] by Ahrén, Bo Pacini, Giovanni Foley, James E Schweizer, Anja Producer: 20051004 In: Diabetes care vol. 28 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	16.	Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes. [electronic resource] by Blüher, Matthias Schweizer, Anja Bader, Giovanni Foley, James E Producer: 20150406 In: Vascular health and risk management vol. 10 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	17.	Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. [electronic resource] by Ahrén, Bo Mathieu, Chantal Bader, Giovanni Schweizer, Anja Foley, James E Producer: 20150129 In: Diabetologia vol. 57 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	18.	Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. [electronic resource] by Rosenstock, Julio Shen, Sharen G Gatlin, Marjorie R Foley, James E Producer: 20030207 In: Diabetes care vol. 25 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	19.	Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. [electronic resource] by Farngren, Johan Persson, Margaretha Schweizer, Anja Foley, James E Ahrén, Bo Producer: 20121218 In: The Journal of clinical endocrinology and metabolism vol. 97 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	20.	Addition of nateglinide to rosiglitazone monotherapy suppresses mealtime hyperglycemia and improves overall glycemic control. [electronic resource] by Fonseca, Vivian Grunberger, George Gupta, Shamita Shen, Sharon Foley, James E Producer: 20040122 In: Diabetes care vol. 26 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

1
2
3
Next
Last

Refine your search

Availability

Authors

Topics

Languages

Your search returned 47 results.